Examkin

Soru

Zorluk: Çok zorMust Be True / Most Strongly Supported

Medical regulatory guidelines for a new category of synthetic pharmaceutical peptides stipulate the following protocols:

• Any synthetic peptide that exhibits neuroplasticity must either cross the blood-brain barrier or be administered intrathecally.
• If a synthetic peptide crosses the blood-brain barrier, it is strictly subject to Schedule II regulatory oversight unless it fully degrades within 24 hours of administration.
• No peptides classified in the newly developed 'Cyto-Alpha' class can be administered intrathecally.
• Furthermore, every peptide in the 'Cyto-Alpha' class exhibits neuroplasticity and has been granted a complete exemption from Schedule II regulatory oversight.

Based on the regulatory protocols above, which of the following statements MUST be true? (Select all that apply.)

  1. Every peptide in the 'Cyto-Alpha' class crosses the blood-brain barrier.Cevap
  2. All peptides in the 'Cyto-Alpha' class fully degrade within 24 hours of administration.Cevap
  3. C
    Any synthetic peptide that is administered intrathecally exhibits neuroplasticity.
  4. D
    Any synthetic peptide that crosses the blood-brain barrier but does not exhibit neuroplasticity must be subject to Schedule II oversight.
  5. E
    No synthetic peptides that fully degrade within 24 hours of administration are subject to Schedule II regulatory oversight.

Cevap

The correct statements are that every peptide in the 'Cyto-Alpha' class crosses the blood-brain barrier, and all peptides in the 'Cyto-Alpha' class fully degrade within 24 hours of administration.
The stimulus establishes a rigorous chain of formal logic. First, all Cyto-Alpha peptides exhibit neuroplasticity. The first rule dictates that any peptide with neuroplasticity must either cross the blood-brain barrier or be administered intrathecally. Because Cyto-Alpha peptides are forbidden from intrathecal administration, they are logically forced into the other option: they must cross the blood-brain barrier. This proves the first correct statement. Next, any peptide crossing the blood-brain barrier must be subject to Schedule II oversight OR fully degrade within 24 hours (translating the 'unless' rule). Since Cyto-Alpha peptides cross the barrier but are explicitly exempt from Schedule II oversight, they must satisfy the alternative condition: fully degrading within 24 hours. This proves the second correct statement.

Adım Adım Çözüm

1
Analyze the mandatory requirements for neuroplasticity.
Cyto-Alpha peptides exhibit neuroplasticity but cannot be administered intrathecally. Therefore, they must cross the blood-brain barrier.
Applies a disjunctive syllogism to the first condition to deduce the primary characteristic of Cyto-Alpha peptides.
2
Evaluate the conditional rule regarding Schedule II oversight.
The rule means: If a peptide crosses the barrier and is NOT Schedule II, it MUST degrade within 24 hours.
Accurately translates the 'unless' modifier into formal conditional logic.
3
Combine deductions specifically for Cyto-Alpha peptides.
Since Cyto-Alpha peptides definitely cross the barrier and are explicitly exempt from Schedule II oversight, they are logically forced to fully degrade within 24 hours.
Synthesizes the derived premise from Step 1 with the given exemptions to find the final necessary truth.

Anahtar Kavram

Complex Deductive Inference and Conditional Logic Chains
Bu soruyu puanla

Konular

Must Be True / Most Strongly Supported

Bu konudan daha fazla soru